MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.630
-0.550
-10.62%
After Hours: 4.750 +0.12 +2.59% 19:59 09/21 EDT
OPEN
4.960
PREV CLOSE
5.18
HIGH
5.05
LOW
4.550
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
2.210
MARKET CAP
27.34M
P/E (TTM)
-1.5026
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc.WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases
GlobeNewswire · 17h ago
ARCA Biopharma files to commence AB201 study for COVID-19
ARCA Biopharma (ABIO) has submitted an Investigational New Drug application under the Coronavirus Treatment Acceleration Program ((CTAP)) to evaluate AB201 for the treatment of patients hospitalized with COVID-19.Pending FDA feedback, ARCA anticipates to
Seekingalpha · 18h ago
ARCA biopharma Announces Submission Of IND Application To US FDA For AB201 As A Potential Treatment For COVID-19
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for
Benzinga · 18h ago
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
Simply Wall St. · 08/17 13:49
ARCA Biopharma Announces Completion Of FDA Pre-IND Consultation Under Coronavirus TreatmentAcceleration Program For AB201 As Potential Treatment For Severe COVID-19
Benzinga · 08/12 12:15
ARCA biopharma EPS beats by $1.85
ARCA biopharma (NASDAQ:ABIO): Q2 GAAP EPS of -$0.73 beats by $1.85. Cash and cash equivalents of $11.04M Shares -1.18%. Press Release
seekingalpha · 08/06 01:48
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseases * ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clin
GlobeNewswire · 08/05 20:15
AMD, SHOP among premarket gainers
Seeking Alpha · 07/29 12:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 272.73K
% Owned: 4.62%
Shares Outstanding: 5.91M
TypeInstitutionsShares
Increased
1
12
New
4
-3.11K
Decreased
3
62.13K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.98%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Director
Robert Conway
Chief Executive Officer/President/Director
Michael Bristow
Chief Operating Officer
Thomas Keuer
Senior Vice President/General Counsel/Secretary
Christopher Ozeroff
Chief Accounting Officer/Vice President - Finance
Brian Selby
Lead Director
Linda Grais
Director
Anders Hove
Director
Daniel Mitchell
Director
Raymond Woosley
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.